Arsenic trioxide, ascorbic acid, filgrastim and erythropoietin for the treatment of myelodysplastic syndromes

被引：0
|
作者：
Khera, N. [1 ]
Miske, H. [1 ]
Shadduck, R. K. [1 ]
Rossetti, J. M. [1 ]
Lister, J. [1 ]
机构：
[1] Western Penn Hosp, Pittsburgh, PA 15224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17519
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A strategy for erythropoietin treatment in myelodysplastic syndromes
    Hast, R
    MEDICAL ONCOLOGY, 1999, 16 (03) : 188 - 190
  • [12] A strategy for erythropoietin treatment in myelodysplastic syndromes
    R Hast
    Medical Oncology, 1999, 16 : 188 - 190
  • [13] Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study
    Welch, John S.
    Klco, Jeffery M.
    Gao, Feng
    Procknow, Elizabeth
    Uy, Geoffery L.
    Stockerl-Goldstein, Keith E.
    Abboud, Camille N.
    Westervelt, Peter
    DiPersio, John F.
    Hassan, Anjum
    Cashen, Amanda F.
    Vij, Ravi
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (09) : 796 - 800
  • [14] Phase II Multicenter Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndrome
    Salvi, Flavia
    Gioia, Daniela
    Corsetri, Maria Teresa
    Pelizzari, Anna Maria
    Messa, Emanuela
    Cilloni, Daniela
    Cametti, Gianni
    Albanesi, Monica
    Colaemma, Angelo
    Marmont, Filippo
    Audisio, Ernesta
    Di Bona, Eros
    Lunghi, Monia
    Ciravegna, Giorgio
    Bonferroni, Margherita
    Barbato, Alfredo
    Banconet, Bruno
    Ferrero, Dario
    Gaidano, Gianluca
    Gallamini, Andrea
    Liberati, Anna Marina
    Pogliani, Enrico
    Rossi, Giuseppe
    Saglio, Giuseppe
    Levis, Alessandro
    BLOOD, 2009, 114 (22) : 389 - 390
  • [15] Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study
    Vey, N
    Bosly, A
    Guerci, A
    Feremans, W
    Dombret, H
    Dreyfus, F
    Bowen, D
    Burnett, A
    Dennis, M
    Ribrag, V
    Casadevall, N
    Legros, L
    Fenaux, P
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2465 - 2471
  • [16] A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes
    de Castro, C.
    Adams, D.
    Rizzieri, D.
    Moore, J.
    Gockerman, J.
    Diehl, L.
    Horwitz, M.
    Edmonds, E.
    Warzecho, J.
    LEUKEMIA RESEARCH, 2009, 33 : S134 - S134
  • [17] Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
    Schiller, Gary J.
    Slack, James
    Hainsworth, John D.
    Mason, James
    Saleh, Mansoor
    Rizzieri, David
    Douer, Dan
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2456 - 2464
  • [18] MYELODYSPLASTIC SYNDROMES - ERYTHROPOIETIN LEVEL AND TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    BOURANTAS, K
    CHRISTOU, L
    TSIARA, S
    SEFERIADIS, K
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1995, 14 (02) : 205 - 210
  • [19] A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
    Wei, Wei
    Zhou, Fan
    Zhang, Yizi
    Guo, Lieping
    Shi, Haotian
    Hou, Jian
    LEUKEMIA RESEARCH, 2012, 36 (06) : 715 - 719
  • [20] Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?
    Bachleitner-Hofmann, T
    Gisslinger, B
    Grumbeck, E
    Gisslinger, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) : 783 - 786
12345